[go: up one dir, main page]

WO2007145862B1 - Extending survival of cancer patients with elevated levels of egf or tgf-alpha - Google Patents

Extending survival of cancer patients with elevated levels of egf or tgf-alpha

Info

Publication number
WO2007145862B1
WO2007145862B1 PCT/US2007/013028 US2007013028W WO2007145862B1 WO 2007145862 B1 WO2007145862 B1 WO 2007145862B1 US 2007013028 W US2007013028 W US 2007013028W WO 2007145862 B1 WO2007145862 B1 WO 2007145862B1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
antibody
cancer
dimerization inhibitor
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/013028
Other languages
French (fr)
Other versions
WO2007145862A3 (en
WO2007145862A2 (en
Inventor
Lukas C Amler
Joachim Moecks
Nusrat Rabbee
Andreas Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Priority to EP07795651A priority Critical patent/EP2035039A2/en
Priority to JP2009514315A priority patent/JP2009539836A/en
Priority to AU2007259171A priority patent/AU2007259171A1/en
Priority to BRPI0712077-0A priority patent/BRPI0712077A2/en
Priority to CA002654584A priority patent/CA2654584A1/en
Priority to MX2008015581A priority patent/MX2008015581A/en
Publication of WO2007145862A2 publication Critical patent/WO2007145862A2/en
Publication of WO2007145862A3 publication Critical patent/WO2007145862A3/en
Publication of WO2007145862B1 publication Critical patent/WO2007145862B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present application describes extending survival in a cancer patient, where the patient is producing an elevated level of EGF or TGF-alpha, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.

Claims

AMENDED CLAIMSreceived by the International Bureau on 14 March 2008 (14.03.08)
1. A method for extending survival of a cancer patient comprising administering a HER dimerization inhibitor to the patient in an amount which extends survival of the patient, wherein the patient is determined to produce an elevated level of epidermal growth factor (EGF) or transforming growth factor alpha (TGF-alpha), and the cancer is selected from the group consisting of ovarian cancer, peritoneal cancer and fallopian rube cancer.
2. The method of claim 1 wherein the patient is determined to produce an elevated level of EGF.
3. The method of claim 2 wherein the patient is found to have an elevated level of EGF in serum of the patient.
4. The method of claim 1 wherein the patient is determined to produce an elevated level of TGF-alpha.
5. The method of claim 4 wherein the patient is found to have an elevated level of TGF-alpha in serum of the patient.
6. The method of claim 1 wherein the HER dimerization inhibitor is a HER2 dimerization inhibitor.
7. The method of claim 1 wherein the HER dimerization inhibitor inhibits HER heterodimerization.
8. The method of claim 1 wherein the HER dimerization inhibitor is a HER antibody.
9. The method of claim 8 wherein the antibody binds to a HER receptor selected from the group consisting of EGFR, HER2, and HER3.
10. The method of claim 9 wherein the antibody binds to HER2.
1 1. The method of claim 10 wherein the HER2 antibody binds to Domain II of HER2 extracellular domain.
12. The method of claim 11 wherein the antibody binds to a junction between domains I3 II and III of HER2 extracellular domain.
13. The method of claim 12 wherein the HER antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.
14. The method of claim 13 wherein the HER dimerization inhibitor is pertuzumab.
15. The method of claim 8 wherein the HER antibody is a naked antibody.
16. The method of claim 8 wherein the HER antibody is an intact antibody.
17. The method of claim 8 wherein the HER antibody is an antibody fragment comprising an antigen binding region.
18. The method of any one of claims 1-17 wherein the cancer is advanced, refractory or recurrent ovarian cancer.
19. The method of any one of claims 1-17 wherein the cancer is platinum resistant ovarian cancer.
20. The method of any one of claims 1-17 wherein the cancer is primary peritoneal or fallopian tube cancer.
21. The method of any one of claims 1-17 wherein the HER dimerization inhibitor is administered as a single anti-tumor agent.
22. The method of any one of claims 1-17 comprising administering a second therapeutic agent to the patient.
23. The method claim 22 wherein the second therapeutic agent is selected from the group consisting of chemotherapeutic agent, HER antibody, antibody directed against a tumor associated antigen, anti-hormonal compound, cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor, COX inhibitor, non-steroidal anti-inflammatory drug, farnesyl transferase inhibitor, antibody that binds oncofetal protein CA 125, HER2 vaccine, HER targeting therapy, Raf or ras inhibitor, liposomal doxorubicin, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286, EMD-7200, a medicament that treats nausea, a medicament that prevents or treats skin rash or standard acne therapy, a medicament that treats or prevents diarrhea, a body temperature-reducing medicament, and a hematopoietic growth factor.
24. The method of claim 23 wherein the second therapeutic agent is a chemotherapeutic agent.
25. The method of claim 24 wherein the chemotherapeutic agent is an antimetabolite chemotherapeutic agent.
26. The method of claim 25 wherein the antimetabolite chemotherapeutic agent is gemcitabine.
27. The method of claim 22 wherein the second therapeutic agent is trastuzumab, erlotinib, or bevacizumab.
28. The method of claim 1 wherein progression free survival (PFS) is extended.
29. The method of claim 1 wherein overall survival (OS) is extended.
30. A method for extending survival of a patient with ovarian, peritoneal, or fallopian tube cancer comprising administering pertuzumab to the patient in an amount which extends survival of the patent, wherein the patient is determined to produce an elevated level of epidermal growth factor (EGF) or transforming growth factor alpha (TGF-alpha).
31. The method of claim 30 wherein patient has ovarian cancer.
32. The method of claim 30 or claim 31 wherein the patient has advanced, refractory or recurrent ovarian cancer.
33. The method of any one of claims 30-32 further comprising administering a chemotherapeutic agent to the patient.
34. The method of claim 33 wherein the chemotherapeutic agent is an antimetabolite chemotherapeutic agent.
35. The method of claim 34 wherein the antimetabolite chemotherapeutic agent is gemcitabine.
36. A method for extending progression free survival (PFS) of a patient with ovarian, peritoneal, or fallopian tube cancer comprising administering pertuzumab to the patient in an amount which extends PFS in the patent, wherein the patient's serum is determined to have an elevated level of epidermal growth factor (EGF) therein.
37. A method for extending progression free survival (PFS) of a patient with ovarian, peritoneal, or fallopian tube cancer comprising administering pertuzumab to the patient in an amount which extends PFS in the patent, wherein the patient's serum is determined to have an elevated level of epidermal growth factor (EGF) and transforming growth factor alpha (TGF- alpha) therein.
38. The method of claim 26 or claim 37, wherein the cancer is ovarian cancer.
39. The method of claim 38 wherein the ovarian cancer is advanced, refractory or recurrent ovarian cancer.
40. A method of selecting a patient for treatment with a HER dimerization inhibitor, comprising treating the patient with the HER dimerization inhibitor if the patient is determined to produce an elevated level of epidermal growth factor (EGF) or transforming growth factor alpha (TGF-alpha).
41. The method of claim 40 wherein the survival of the patient is extended relative to the survival of a patient who does not produce an elevated level of EGF or TGF-alpha and receives the same treatment.
42. The method of claim 41 wherein the survival is overall survival (OS).
43. The method of claim 41 wherein the survival is progression free survival (PFS).
44. The method of claim 41 wherein the HER dimerization inhibitor is a HER2 dimerization inhibitor.
45. The method of claim 41 wherein the HER dimerization inhibitor inhibits HER heterodimerization.
46. The method of claim 31 wherein the HER dimerization inhibitor is a HER antibody.
47. The method of claim 46 wherein the antibody binds to a HER receptor selected from the group consisting of EGFR, HER2, and HER3.
48. The method of claim 47 wherein the antibody binds to HER2.
49. The method of claim 48 wherein the HER2 antibody binds to Domain II of HER2 extracellular domain.
50. The method of claim 49 wherein the antibody binds to a junction between domains I, II and III of HER2 extracellular domain.
51. The method of claim 50 wherein the HER antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.
52. The method of claim 51 wherein the HER dimerization inhibitor is pertuzumab.
53. The method of claim 46 wherein the HER antibody is a naked antibody.
54. The method of claim 46 wherein the HER antibody is an intact antibody.
55. The method of claim 46 wherein the HER antibody is an antibody fragment comprising an antigen binding region.
56. The method of any one of claims 40-55, further comprising treating said patient with a chemotherapeutic agent.
57. The method of claim 56 wherein the chemotherapeutic agent is gemcitabine.
58. A kit comprising a HER dimerization inhibitor and a package insert or label indicating a beneficial use for the HER dimerization inhibitor if the patient to be treated produces an elevated level of epidermal growth factor (EGF) or transforming growth factor alpha (TGF- alpha).
59. The method of claim 58 wherein the cancer is ovarian cancer, peritoneal or fallopian tube cancer.
60. The method of claim 38 wherein the beneficial use is extension of survival.
61. The method of claim 60 wherein the survival is progression-free survival.
62. The method of any one of claims 58-61 wherein the HER dimerization inhibitor is an antibody.
63. The method of claim 62 wherein the antibody is a HER2 antibody.
64. The method of claim 63 wherein the antibody is pertuzumab.
65. A method of promoting a HER dimerization inhibitor to treat patients producing an elevated level of epidermal growth factor (EGF) or transforming growth factor alpha (TGF-alpha).
66. The method of claim 65 wherein the promotion is in the form of a written material.
67. The method of claim 66 wherein the promotion is in the form of a package insert.
68. A method of selecting a cancer patient for treatment with a HER dimerization inhibitor, comprising determining the level of epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-α) in said cancer patient, and selecting said cancer patient for treatment with said HER dimerization inhibitor, if said patient is determined to produce an elevated level of EGF or TGF-α.
69. The method of claim 68 wherein the patient is determined to produce an elevated level of EGF.
70. The method of claim 69 wherein the patient is determined to have an elevated level of EGF in a biological fluid of said patient.
71. The method of claim 70 wherein the biological fluid is selected from the group consisting of blood, plasma, serum, urine, saliva, and ascites fluid.
72. The method of claim 71 wherein the biological fluid is serum.
73. The method of claim 68 wherein the patient is determined to produce an elevated level of TGF-α.
74. The method of claim 73 wherein the patient is determined to produce an elevated level of TGF-α in a biological fluid of said patient.
75. The method of claim 74 wherein the biological fluid is selected from the group consisting of blood, plasma, serum, urine, saliva, and ascites fluid.
76. The method of claim 75 wherein the biological fluid is serum.
77. The method of claim 68 wherein the cancer is selected from the group consisting of ovarian cancer, peritoneal cancer, and fallopian tube cancer.
78. The method of claim 68 wherein the HER dimerization inhibitor is a HER2 dimerization inhibitor.
79. The method of claim 68 wherein the HER dimerization inhibitor inhibits HER heterodimerization.
80. The method of claim 68 wherein the HER dimerization inhibitor is a HER antibody.
81. The method of claim 80 wherein the HER antibody binds to a HER receptor selected from the group consisting of EGFR, HER2, and HER3.
82. The method of claim 81 wherein the antibody binds to HER2.
83. The method of claim 82 wherein the antibody binds to Domain II of HER2 extracellular domain.
84. The method of claim 82 wherein the antibody binds to a junction between domains I, II and III of HER2 extracellular domain.
85. The method of claim 82 wherein the antibody comprises the variable light and the variable heavy amino acid sequences in SEQ ID NOs 3 and 4, respectively.
86. The method of claim 85 wherein the dimerization inhibitor is pertuzumab.
87. The method of claim 80 wherein the antibody is a naked antibody.
88. The method of claim 80 wherein the antibody is an intact antibody.
89. The method of claim 80 wherein the antibody is an antibody fragment comprising an antigen binding region.
90. The method of any one of claims 68-89 wherein the cancer is advanced, refractory or recurrent ovarian cancer.
91. The method of any one of claims 68-89 wherein the cancer is platinum resistant ovarian cancer.
92. The method of any one of claims 68-89 wherein the cancer is primary peritoneal or fallopian tube cancer.
PCT/US2007/013028 2006-05-01 2007-05-31 Extending survival of cancer patients with elevated levels of egf or tgf-alpha Ceased WO2007145862A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP07795651A EP2035039A2 (en) 2006-06-05 2007-05-31 Extending survival of cancer patients with elevated levels of egf or tgf-alpha
JP2009514315A JP2009539836A (en) 2006-06-05 2007-05-31 Prolonged survival of cancer patients with elevated levels of EGF or TGF-α
AU2007259171A AU2007259171A1 (en) 2006-06-05 2007-05-31 Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
BRPI0712077-0A BRPI0712077A2 (en) 2006-05-01 2007-05-31 prolongation of survival of cancer patients with elevated levels of egf or tgf-alpha
CA002654584A CA2654584A1 (en) 2006-06-05 2007-05-31 Extending survival of cancer patients with elevated levels of egf or tgf-alpha
MX2008015581A MX2008015581A (en) 2006-06-05 2007-05-31 Extending survival of cancer patients with elevated levels of egf or tgf-alpha.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81123406P 2006-06-05 2006-06-05
US60/811,234 2006-06-05

Publications (3)

Publication Number Publication Date
WO2007145862A2 WO2007145862A2 (en) 2007-12-21
WO2007145862A3 WO2007145862A3 (en) 2008-02-28
WO2007145862B1 true WO2007145862B1 (en) 2008-05-02

Family

ID=38691718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013028 Ceased WO2007145862A2 (en) 2006-05-01 2007-05-31 Extending survival of cancer patients with elevated levels of egf or tgf-alpha

Country Status (13)

Country Link
US (1) US20080038271A1 (en)
EP (1) EP2035039A2 (en)
JP (1) JP2009539836A (en)
KR (1) KR20090019890A (en)
CN (1) CN101495142A (en)
AR (1) AR061230A1 (en)
AU (1) AU2007259171A1 (en)
BR (1) BRPI0712077A2 (en)
CA (1) CA2654584A1 (en)
CL (1) CL2007001602A1 (en)
MX (1) MX2008015581A (en)
TW (1) TW200815472A (en)
WO (1) WO2007145862A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
KR20110050567A (en) 2004-07-22 2011-05-13 제넨테크, 인크. HER2 antibody composition
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
TWI441646B (en) * 2005-01-21 2014-06-21 Genentech Inc Use of pertuzumab for the preparation of a medicament for treating cancer in a human patient
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US20100113299A1 (en) * 2008-10-14 2010-05-06 Von Hoff Daniel D Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (en) * 2006-05-18 2011-08-23 Molecular Profiling Inst Inc method for determining medical intervention for a disease state, method for identifying drug therapy capable of interacting with a molecular target, and system for determining individualized medical intervention for a disease state
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
PL2132573T3 (en) 2007-03-02 2014-09-30 Genentech Inc Predicting response to a her dimerisation inhbitor based on low her3 expression
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
JP2012517238A (en) * 2009-02-11 2012-08-02 カリス エムピーアイ インコーポレイテッド Molecular profiling of tumors
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102770456B (en) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 Multispecific antibodies, antibody analogs, compositions and methods
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
PL2515941T3 (en) * 2009-12-21 2020-04-30 F. Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
CN103003424B (en) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 Antibodies that bind transforming growth factor alpha and have proliferation inhibitory activity against cancers with mutations in the Ras gene
JP2013537522A (en) * 2010-07-19 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Methods for identifying patients with increased likelihood of response to anti-cancer therapy
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
FI4241849T3 (en) 2011-10-14 2024-11-12 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
RU2737727C2 (en) 2013-04-16 2020-12-02 Дженентек, Инк. Versions of pertuzumab and their analytical characteristics
WO2015103355A1 (en) 2014-01-01 2015-07-09 Medivation Technologies, Inc. Compounds and methods of use
RU2020120593A (en) 2014-04-25 2020-09-01 Дженентек, Инк. METHODS FOR TREATMENT OF EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB
ES2984592T3 (en) 2015-05-30 2024-10-30 Hoffmann La Roche Treatment procedures for previously untreated HER2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
KR20190096384A (en) 2017-03-02 2019-08-19 제넨테크, 인크. HER2-positive breast cancer adjuvant treatment
CN110536969A (en) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 ERBB2/HER2 mutations in the transmembrane or juxtamembrane domain
MX2022002980A (en) 2019-09-16 2022-04-06 Amgen Inc METHOD FOR THE EXTERNAL STERILIZATION OF A DRUG SUPPLY DEVICE.
CN115916834A (en) 2020-06-29 2023-04-04 基因泰克公司 Fixed-dose combination of pertuzumab plus trastuzumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100850389B1 (en) * 1999-06-25 2008-08-04 제넨테크, 인크. Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies
GT200500155A (en) * 2004-06-16 2006-05-15 PLATINUM-RESISTANT CANCER THERAPY
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor

Also Published As

Publication number Publication date
CN101495142A (en) 2009-07-29
JP2009539836A (en) 2009-11-19
WO2007145862A3 (en) 2008-02-28
BRPI0712077A2 (en) 2012-01-17
US20080038271A1 (en) 2008-02-14
AR061230A1 (en) 2008-08-13
KR20090019890A (en) 2009-02-25
CL2007001602A1 (en) 2008-03-14
MX2008015581A (en) 2008-12-17
AU2007259171A1 (en) 2007-12-21
EP2035039A2 (en) 2009-03-18
WO2007145862A2 (en) 2007-12-21
TW200815472A (en) 2008-04-01
CA2654584A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2007145862B1 (en) Extending survival of cancer patients with elevated levels of egf or tgf-alpha
Khalil et al. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer
RU2404806C2 (en) Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
Normanno et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Mendelsohn Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture
Neve et al. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function
JP2010520225A5 (en)
JP2008531576A5 (en)
RU2007131693A (en) INTRODUCTION OF FIXED DOSES OF HER ANTIBODIES
JP2008528486A5 (en)
Emde et al. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
WO2012018404A2 (en) Use of her3 binding agents in prostate treatment
SI2719708T1 (en) Material and methods for treating or preventing HER-3 associated diseases
WO2013123588A9 (en) Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
RU2011146339A (en) COMBINED THERAPY USING AGENT (S) AGAINST IGFR AND SPECIFIC IGF-1R INHIBITORS
Fu et al. Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer
WO2015131822A1 (en) Antibody-drug conjugate pertuzumab-mcc-dm1, composition of pertuzumab-mcc-dm1 and trastuzumab and uses thereof
Rysman et al. Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
CA2916552C (en) Divalent vaccine compositions and the use thereof for treating tumors
JP6368811B2 (en) HER3 inhibitors for modulating radiosensitivity
Cao et al. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer
WO2009125039A1 (en) Antibodies for treating cancer
Kim Cetuximab as a single agent or in combination with chemotherapy in lung cancer
US20150037336A1 (en) Combination of hb-egf binding protein and egfr inhibitor
Maegawa et al. Growth Stimulation of Non–Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780027466.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795651

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009514315

Country of ref document: JP

Ref document number: 195742

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2654584

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/015581

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007259171

Country of ref document: AU

Ref document number: 10164/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007795651

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097000041

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007259171

Country of ref document: AU

Date of ref document: 20070531

Kind code of ref document: A